Прогностическое значение биологического подтипа для выбора хирургической тактики лечения при раннем раке молочной железы (Обзор литературы)

Целью данного систематического обзора является выявление зависимости подтипа рака молочной железы и риска развития местно-регионарного рецидива после органосохранного лечения и радикальной мастэктомии. Основными предикторами в развитии рецидива при РМЖ можно считать молодой возраст, степень злокачественности опухоли, размер опухолевого узла, наличие лимфоваскулярной инвазии или поражение лимфатических узлов и неблагоприятные подтипы опухоли. В настоящее время нет однозначных данных о выборе хирургической тактики лечения для различных биологических подтипов, однако эффективная системная терапия, а также лучевая терапия уменьшают частоту местных рецидивов после выполнения органосохранных операций при неблагоприятных подтипах опухолей, и, по результатам исследований, общая и безрецидивная выживаемость являются сопоставимыми, как и при проведении радикальной мастэктомии. Органосохранное лечение может быть выполнено у молодых пациенток с неблагоприятными подтипами опухолей при условии использования всех возможностей современной химиолучевой терапии.

рак молочной железы, биологические подтипы, прогноз, радикальная мастэктомия, органосохранное лечение, рецидив

1. Давыдов МИ, Аксель ЕМ. Статистика злокачественных новообразований в России и странах СНГ в 2013 году. Вестник РОНЦ им. Н.Н. Блохина РАМН, 2015.

2. Переводчикова НИ, Стенина МБ. Лекарственная терапия рака молочной железы. М.: Практика, 2014.

3. Стенина МБ, Жукова ЛГ, Королева ИА, Пароконная АА и соавт. Практические рекомендации по лекарственному лечению злокачественных опухолей. Инвазивный рак молочной железы. М., Злокачественные опухоли. 2017;7(3):114-115.

4. Семиглазов ВФ, Палтуев РМ, Семиглазов ВВ, Манихас АГ и соавт. Ранний рак молочной железы: прогностическое значение биологических подтипов (анализ кумулятивной базы данных ФГБУ НИИ онкологии им. Н.Н. Петрова» Минздравсоцразвития. Злокачественные опухоли. 2012;2(2):12-18.

5. Ferlay J, Soerjomataram I, Dikshit R, Eser S. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2014. International Journal of Cancer. 2014;136(5):E359-E386.

6. Gucalp A, Gupta G, Pilewskie M, Sutton E, Norton L. Advances in managing breast cancer: a clinical update. 2014/ F1000Prime Reports, 6.

7. Beaber E, Buist D, Barlow W, Malone K. Recent Oral Contraceptive Use by Formulation and Breast Cancer Risk among Women 20 to 49 Years of Age. Cancer Research. 2014;74(15):4078-4089.

8. Kennecke H, Yerushalmi R, Woods R, Cheang M, Voduc D, Speers C, Nielsen T, Gelmon K. Metastatic Behavior of Breast Cancer Subtypes. Journal of Clinical Oncology. 2010;28(20):3271-3277.

9. Senn H. St. Gallen Consensus 2013: Optimizing and Personalizing Primary Curative Therapy of Breast Cancer Worldwide. Breast Care. 2013;8(2):101-101.

10. Arvold N, Taghian A, Niemierko A, Abi Raad R. Age, Breast Cancer Subtype Approximation, and Local Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology. 2011;29(29):3885-3891.

11. Wu X, Baig A, Kasymjanova G, Kafi K, Holcroft C, Mekouar H, Carbonneau A, Bahoric B, Sultanem K, Muanza T Pattern of Local Recurrence and Distant Metastasis in Breast Cancer By Molecular Subtype. Cureus. 2016.

12. Tran B, Bedard P. Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Research. 2011;13(6).

13. Chen S, Huang L, Chen C, Shao Z. Progesterone receptor loss identifies luminal-type local advanced breast cancer with poor survival in patients who fail to achieve a pathological complete response to neoadjuvant chemotherapy. Oncotarget. 2015;6(20).

14. Prat A, Cheang M, Martin M, Parker J. Prognostic Significance of Progesterone Receptor-Positive Tumor Cells Within Immunohistochemically Defined Luminal A Breast Cancer. Journal of Clinical Oncology. 2011;31(2):203-209.

15. Laurberg T, Alsner J, Tramm T, Jensen V, Lyngholm C. Impact of age, intrinsic subtype and local treatment on longterm local-regional recurrence and breast cancer mortality among low-risk breast cancer patients. Acta Oncologica. 2016;56(1):59-67.

16. Viale G, Regan M, Maiorano E, Mastropasqua MA. Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98. Journal of Clinical Oncology. 2007;25(25):3846-3852.

17. Engel J, Eckel R, Aydemir Ü. Determinants and prognoses of locoregional and distant progression in breast cancer. International Journal of Radiation. International Journal of Radiation Oncology Biology Physics. 2003;55(5):1186-1195.

18. Albert J, Buchholz T. Basal subtype of invasive breast cancer is associated with a higher risk of true recurrence after conventional breast-conserving therapy. Breast Diseases: A Year Book Quarterly. 2012;23(3):288-289.

19. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673-1684.

20. Liedtke C, Mazouni C, Hess K, André F. Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer. Journal of Clinical Oncology. 2008;26(8):1275-1281.

21. Gangi A, Chung A, Mirocha J, Liou D. Breast-Conserving Therapy for Triple-Negative Breast Cancer. JAMA Surgery. 2014;149(3):252.

22. Abdulkarim B, Cuartero J, Hanson J, Deschênes J. Increased Risk of Locoregional Recurrence for Women With T1-2N0 Triple-Negative Breast Cancer Treated With Modified Radical Mastectomy Without Adjuvant Radiation Therapy Compared With Breast-Conserving Therapy. Journal of Clinical Oncology. 2011;29(21):2852-2858.

23. Adkins F, Gonzalez-Angulo A, Lei X, Hernandez-Aya L. Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation. Annals of Surgical Oncology. 2011;18(11):3164-3173.

24. Zumsteg Z, Morrow M, Arnold B, Zheng J. Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer. Annals of Surgical Oncology. 2013;20(11):3469-3476.

25. Yang T Morrow M, Modi S, Zhang Z. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation. Annals of Surgical Oncology. 2015;22(S3):495-501.

26. Wong F, Chua E. Hormone Receptors and HER-2 Status as Surrogates for Histological Subtypes Prognosticate for Disease Control in Node Negative Asian Breast Cancer Patients Treated with Breast Conservation Therapy. International Journal of Radiation Oncology Biology Physics. 2011;75(3):S183-S184.

27. Siponen E, Joensuu H, Vironen J, Heikkilä P. Ipsilateral breast recurrence after breast conserving surgery in patients with small (≤2 cm) breast cancer treated with modern adjuvant therapies Vaalavirta. European Journal of Surgical Oncology (EJSO). 2011;37(1):25-31.

28. Abdulkaraim H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, Moo T The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy. The Breast Journal. 2017:S183-S184.

29. Braunstein L, Taghian A, Niemierko A, Salama L. Breast-cancer subtype, age, and lymph node status as predictors of local recurrence following breast-conserving therapy. Breast Cancer Research and Treatment. 2016;161(1):173-179.

30. Mannino М, Yarnold J. Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld? Radiotherapy and Oncology. 2009;90(1):14-22.

31. Nguyen P, Taghian A, Katz M et al. Breast Cancer Subtype Approximated by Estrogen Receptor, Progesterone Receptor, and HER-2 Is Associated With Local and Distant Recurrence After Breast-Conserving Therapy. Journal of Clinical Oncology. 2009;26(14):2373-2378.

32. Lowery A, Kell M, Glynn R, Kerin M, Sweeney K. Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype. Breast Cancer Research and Treatment. Breast Cancer Research and Treatment. 2011;133(3):831-841.

33. Wang J, Xie X, Wang X, Tang J. Locoregional and distant recurrences after breast conserving therapy in patients with triple-negative breast cancer: A meta-analysis. Surgical Oncology. 2013;22(4):247-255.

34. Moran M. Radiation therapy in the locoregional treatment of triple-negative breast cancer. The Lancet Oncology. 2015;16(3):e113-e122.

35. King T, Radosa J, Eaton A, Stempel M, Khander A. Evaluation of Local and Distant Recurrence Patterns in Patients with Triple-Negative Breast Cancer According to Age. Annals of Surgical Oncology. 2016;24(3):698-704.

36. Gnant M., Harbeck N et al. St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment. Breast Care. 2017;12(2):102-107.

37. Chen Q., Wang X, Lin P, Zhang J. The different outcomes between breast-conserving surgery and mastectomy in tri ple-negative breast cancer: a population-based study from the SEER 18 database. Oncotarget. 2016;8(3).

38. Alabdulkareem H, Pinchinat T, Khan S, Landers A, Christos P, Simmons R, Moo T The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy. The Breast Journal. 2017:S183-S184.